Zhitong Finance App News, Shisi Pharmaceutical Group (02005.HK) announced that the Group's ziprasidone hydrochloride has been approved by the China National Drug Administration for registration as an active ingredient for use in marketed formulations. Ziprasidone hydrochloride is a novel atypical broad-spectrum antipsychotic. It is a second-generation antipsychotic drug, mainly used to treat schizophrenia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.